Brief: Immix Biopharma Subsidiary Nexcella Enters Into U.S. Gmp Manufacturing Agreement To Expand Ongoing Nxc-201 Phase 1B/2 Clinical Trial To The U.S.

Immix Biopharma

15/02/2023 14:16

Feb 15 (Reuters) - Immix Biopharma Inc  IMMX.O :
    * IMMIX BIOPHARMA SUBSIDIARY NEXCELLA ENTERS INTO U.S. GMP
MANUFACTURING AGREEMENT TO EXPAND ONGOING NXC-201 PHASE 1B/2
CLINICAL TRIAL TO THE U.S.
    * NEXCELLA - INITIATES PROCESS OF BRINGING NXC-201 TO UNITED
STATES BY ENTERING INTO AN AGREEMENT WITH A WELL-KNOWN GMP CELL
THERAPY MANUFACTURER
    * NEXCELLA - U.S. MANUFACTURING SITE EXPECTED TO SUPPLY
NXC-201
MATERIAL FOR PHASE 1B/2 TRIAL IN U.S. AFTER IND SUBMISSION TO
FDA AND APPROVAL
    * NEXCELLA - PLANS TO INITIATE A PRE-IND MEETING WITH FDA,
SUBMIT
IND APPLICATION, OBTAIN APPROVAL FOR A PHASE 1B/2 OF NXC-201
STUDY

Source text for Eikon:  ID:nGNX2R5Kjv 
Further company coverage:  IMMX.O 
 ((Reuters.Briefs@thomsonreuters.com;))